PHH Company Report

Analyst Coverage

Research analysts who have asked questions during PHH earnings calls.

Keefe, Bruyette & Woods

3 questions for PHH

Wedbush Securities

3 questions for PHH

Compass Point

2 questions for PHH

TD Cowen

1 question for PHH

Bank of America

1 question for PHH

Recent press releases and 8-K filings for PHH.

Park Ha Biological Technology Co., Ltd. Approves Dual-Class Share Structure and Share Consolidation

PHH

Proxy Vote Outcomes

Park Ha Biological Technology Co., Ltd. held its 2025 Annual General Meeting on October 3, 2025, where a quorum was reached with 21,872,753 ordinary shares voted out of 33,874,403 issued and outstanding.
Shareholders approved an increase in authorized share capital to US$300,000, divided into 15,000,000,000 ordinary shares of par value US$0.00002 each, which are re-classified into 12,000,000,000 Class A ordinary shares (1 vote per share) and 3,000,000,000 Class B ordinary shares (20 votes per share).
The existing 33,874,403 ordinary shares were re-designated as Class A Ordinary Shares, and 19,050,000 Class A Ordinary Shares held by Xiaoqiu Zhang were surrendered for nil consideration and reissued as Class B Ordinary Shares, concentrating voting power.
A share consolidation (reverse stock split) was approved, with a ratio from one-for-five to one-for-thirty, to be determined by the Board within one year.

Oct 8, 2025, 11:00 AM

Park Ha Biological Technology Co., Ltd. Announces Six-Month Financial Performance Ending April 30, 2025

PHH

Earnings

Revenue Acceleration/Inflection

Park Ha Biological Technology Co., Ltd. reported a 45% increase in total revenue to $1,239,197 for the six months ended April 30, 2025, compared to $852,928 for the same period in 2024. However, the company recorded a net loss of $19,835,994 for the period, a significant decline from a net income of $48,900 in the prior year, resulting in an EPS of ($0.74).
The substantial net loss was primarily attributed to a 4464% increase in general and administrative expenses, which surged to $20,632,549 for the six months ended April 30, 2025, largely driven by $19,950,000 in share-based compensation expense.
Cash and cash equivalents increased to $1,351,285 as of April 30, 2025, from $547,498 as of October 31, 2024, primarily due to $3,833,511 in net cash provided by financing activities, mainly from the issuance of shares.
The number of franchisees decreased to 39 as of April 30, 2025, from 43 as of April 30, 2024.